Investigational Two-Drug Regimen of Rilpivirine and Dolutegravir
Shows Efficacy As Maintenance Therapy in Patients Who Have Already
Achieved Viral Suppression -
CORK, Ireland,
Dec. 19, 2016 - /PRNewswire/ -- Janssen Sciences Ireland UC (Janssen)
today announced that two Phase III studies to evaluate the safety and
efficacy of switching virologically suppressed patients from a three or
four drug (integrase inhibitor-, non-nucleoside reverse transcriptase
inhibitor-, or boosted protease inhibitor-based) antiretroviral regimen
to the two drug regimen of rilpivirine (Janssen) and dolutegravir (ViiV
Healthcare) met the primary endpoint of non inferiority at week 48.
The primary endpoint in both studies was evaluated as the proportion
of patients with plasma HIV-1 RNA <50 copies per milliliter (c/mL) at
Week 48. Detailed study results will be presented at an upcoming
scientific meeting. The safety profile for rilpivirine and dolutegravir
in the two studies was consistent with the product labelling for each
medicine.
"HIV has become a chronic, long-term condition in many parts of the
world thanks to the availability of more than 20 approved medicines. As
physicians, and those living with HIV, consider life-long treatment
they must balance efficacy and the side effects of treatment," says Lawrence M. Blatt,
Global R&D Head, Infectious Diseases & Vaccines, Janssen. "We
are committed to exploring new combination therapies to improve the
lives of those facing life-long HIV treatment and these important
results for a two-drug regimen support those efforts."
It is anticipated that regulatory submissions for the investigational
two-drug regimen of rilpivirine and dolutegravir as a single tablet
will be made in 2017.
About the SWORD Phase III Program for dolutegravir (Tivicay®) and rilpivirine (Edurant®)
The Phase III program evaluates the efficacy, safety, and
tolerability of switching to dolutegravir plus rilpivirine from current
integrase inhibitor-, non-nucleoside reverse transcriptase inhibitor-,
or boosted protease inhibitor-based antiretroviral regimen in
HIV-1-infected adults who are virologically suppressed with a three or
four drug regimen. In the clinical trials, dolutegravir and rilpivirine
are provided as individual tablets. SWORD-1 (NCT02429791) and SWORD-2
(NCT02422797) are replicate 148-week, randomised, open-label,
non-inferiority studies to assess the antiviral activity and safety of a
two-drug, daily oral regimen of dolutegravir plus rilpivirine compared
with current antiretroviral therapy.
The primary endpoint is proportion of patients with plasma HIV-1 RNA
<50 copies per milliliter (c/mL) at Week 48. Key secondary endpoints
include evaluation of the development of viral resistance, measurements
of safety and tolerability, and changes in renal, bone and
cardiovascular biomarkers. The study also includes exploratory measures
to assess change in health-related quality of life, willingness to
switch, and adherence to treatment regimens.
EDURANT® (Rilpivirine)
EDURANT® (rilpivirine) is a prescription HIV medicine that is used
with other antiretroviral medicines to treat Human Immunodeficiency
Virus-1 (HIV-1) in patients:
- Who have never taken HIV medicines before, and
- Who have an amount of HIV in their blood (called "viral load") that is no more than 100,000 copies/mL. Your healthcare professional will measure your viral load
EDURANT® should be taken in combination with other HIV medicines.
Your healthcare professional will work with you to find the right
combination of HIV medicines.
It is important that you remain under the care of your healthcare professional during treatment with EDURANT®
EDURANT® is not recommended for patients less than 12 years of age
EDURANT® does not cure HIV infection or AIDS. You should remain on
your HIV medications without stopping to ensure that you control your
HIV infection and decrease the risk of HIV-related illnesses. Ask your
healthcare professional about how to prevent passing HIV to other
people.
Please read Important Safety Information below, and talk to your healthcare professional to learn if EDURANT® is right for you.
Important Safety Information
Can EDURANT® be taken with other medicines?
EDURANT® may affect the way other medicines work and other medicines
may affect how EDURANT® works and may cause serious side effects. If you
take certain medicines with EDURANT®, the amount of EDURANT® in your
body may be too low and it may not work to help control your HIV
infection, and the HIV virus in your body may become resistant to
EDURANT® or other HIV medicines that are like it. To help get the right
amount of medicine in your body, you should always take EDURANT® with a
meal. A protein drink alone does not replace a meal.
Do not take EDURANT® if:
- Your HIV infection has been previously treated with HIV medicines
- You are taking any of the following medicines:
- Anti-seizure medicines: carbamazepine (Carbatrol®, Equetro®, Tegretol®, Tegretol-XR®, Teril®, Epitol®), oxcarbazepine (Trileptal®), phenobarbital (Luminal®), phenytoin (Dilantin®, Dilantin-125®, Phenytek®)
- Anti-tuberculosis (anti-TB) medicines: rifampin (Rifater®, Rifamate®, Rimactane®, Rifadin®), rifapentine (Priftin®)Proton pump inhibitor (PPI) medicine for certain stomach or intestinal problems: esomeprazole (Nexium®, Vimovo®), lansoprazole (Prevacid®), omeprazole (Prilosec®, Zegerid®), pantoprazole sodium (Protonix®), rabeprazole (Aciphex®)
- More than 1 dose of the steroid medicine dexamethasone or dexamethasone sodium phosphate
- St. John's wort (Hypericum perforatum)
Especially tell your doctor if you take:
- Rifabutin (Mycobutin®), a medicine to treat some bacterial infections. Talk to your doctor or pharmacist about the right amount of EDURANT® you should take if you also take rifabutin
- Medicines used to treat HIV
- An antacid medicine that contains aluminum, magnesium hydroxide, or calcium carbonate. Take antacids at least 2 hours before or at least 4 hours after you take EDURANT®
- Medicines to block acid in your stomach, including cimetidine (Tagamet®), famotidine (Pepcid®), nizatidine (Axid®), or ranitidine hydrochloride (Zantac®). Take these medicines at least 12 hours before or at least 4 hours after you take EDURANT®
- Any of these medicines (if taken by mouth or injection): clarithromycin (Biaxin®), erythromycin (E-Mycin®, Eryc®, Ery-Tab®, PCE®, Pediazole®, Ilosone®), fluconazole (Diflucan®), itraconazole (Sporanox®), ketoconazole (Nizoral®), methadone (Dolophine®), posaconazole (Noxafil®), telithromycin (Ketek®), voriconazole (Vfend®)
This is not a complete list of medicines. Before starting EDURANT®,
be sure to tell your healthcare professional about all the medicines you
are taking or plan to take, including prescription and nonprescription
medicines, vitamins, and herbal supplements.
Before taking EDURANT®, also tell your healthcare professional if you
have had or currently have liver problems (including hepatitis B or C),
have ever had a mental health problem, are pregnant or planning to
become pregnant, or breastfeeding. It is not known if EDURANT® will harm
your unborn baby.
You and your healthcare professional will need to decide if taking EDURANT® is right for you.
Do not breastfeed if you are taking EDURANT®. You should not
breastfeed if you have HIV because of the chance of passing HIV to your
baby
What are the possible side effects of EDURANT®? EDURANT® can cause serious side effects including:
- Severe skin rash and allergic reactions. Call your doctor right away if you get a rash. Stop taking EDURANT® and seek medical help right away if you get a rash with any of the following symptoms: severe allergic reaction causing swelling of the face, eyes, lips, mouth, tongue, or throat (which may lead to difficulty swallowing or breathing); mouth sores or blisters on your body; inflamed eye (conjunctivitis); fever; dark urine; or pain on the right side of the stomach area (abdominal pain)
- Depression or mood changes. Tell your doctor right away if you have any of the following symptoms: feeling sad or hopeless, feeling anxious or restless, have thoughts of hurting yourself (suicide), or have tried to hurt yourself
- Liver problems. People with a history of hepatitis B or C virus infection or who have certain liver function test changes may have an increased risk of developing new or worsening liver problems during treatment. Liver problems were also reported during treatment in some people without a history of liver disease. Your healthcare professional may need to do tests to check liver function before and during treatment
- Changes in body shape or body fat have been seen in some patients taking HIV medicines. The exact cause and long-term health effects of these conditions are not known
- Changes in your immune system (immune reconstitution syndrome).
- Your immune system may get stronger and begin to fight infections. Tell your healthcare professional right away if you start having any new symptoms of infection
- Other common side effects of EDURANT® include depression, headache, trouble sleeping (insomnia), and rash.
This is not a complete list of all side effects. If you experience
these or other symptoms, contact your healthcare professional right
away. Do not stop taking EDURANT® or any other medications without first
talking to your healthcare professional.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Janssen Products, LP at 1-800-JANSSEN (1-800-526-7736).
Please see full Product Information for more details.
TIVICAY® (dolutegravir) tablets
Professional Indication(s) and Important Safety Information
Indications and Usage
TIVICAY is a human immunodeficiency virus type 1 (HIV-1) integrase
strand transfer inhibitor (INSTI) indicated in combination with other
antiretroviral agents for the treatment of HIV-1 infection in adults and
pediatric patients weighing at least 30 kg.
Limitations of Use:
- Use of TIVICAY in INSTI-experienced patients should be guided by the number and type of baseline INSTI substitutions. The efficacy of TIVICAY 50 mg twice daily is reduced in patients with an INSTI-resistance Q148 substitution plus 2 or more additional INSTI-resistance substitutions including T66A, L74I/M, E138A/K/T, G140S/A/C, Y143R/C/H, E157Q, G163S/E/K/Q, or G193E/R
Important Safety Information
Contraindications:
TIVICAY is contraindicated in patients:
- with previous hypersensitivity reaction to dolutegravir
- receiving dofetilide (antiarrhythmic)
Hypersensitivity Reactions:
- Hypersensitivity reactions have been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury. The events were reported in <1% of subjects receiving TIVICAY in Phase 3 clinical trials
- Discontinue TIVICAY and other suspect agents immediately if signs or symptoms of hypersensitivity reactions develop, as a delay in stopping treatment may result in a life-threatening reaction. Monitor clinical status, including liver aminotransferases, and initiate appropriate therapy if hypersensitivity reaction is suspected
Effects on Serum Liver Biochemistries in Patients with Hepatitis B or C Co-infection:
- Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with use of TIVICAY. In some cases the elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation, particularly in the setting where anti-hepatitis therapy was withdrawn
- Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended in patients with underlying hepatic disease such as hepatitis B or C
Fat Redistribution or accumulation has been observed in patients receiving antiretroviral therapy.
Immune Reconstitution Syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported.
Adverse Reactions: The most commonly reported (?2%) adverse
reactions of moderate to severe intensity in treatment-naïve adult
subjects in any one trial receiving TIVICAY in a combination regimen
were insomnia (3%), fatigue (2%), and headache (2%).
Drug Interactions:
- Coadministration of TIVICAY with certain inducers of UGT1A and/or CYP3A may reduce plasma concentrations of dolutegravir and require dose adjustments of TIVICAY
- Administer TIVICAY 2 hours before or 6 hours after taking polyvalent cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, TIVICAY and supplements containing calcium or iron can be taken with food
- Consult the full Prescribing Information for TIVICAY for more information on potentially significant drug interactions, including clinical comments
Pregnancy: TIVICAY should be used during pregnancy only if the
potential benefit justifies the potential risk. An Antiretroviral
Pregnancy Registry has been established.
Nursing Mothers: Breastfeeding is not recommended due to the
potential for HIV transmission and the potential for adverse reactions
in nursing infants.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995
regarding development of treatment and prevention options for HIV. The
reader is cautioned not to rely on these forward-looking statements.
These statements are based on current expectations of future events. If
underlying assumptions prove inaccurate or known or unknown risks or
uncertainties materialize, actual results could vary materially from the
expectations and projections of Janssen Sciences Ireland UC, any of the
other Janssen Pharmaceutical Companies and/or Johnson & Johnson.
Risks and uncertainties include, but are not limited to: challenges and
uncertainties inherent in product development, including uncertainty of
clinical success and obtaining regulatory approvals; competition,
including technological advances, new products and patents attained by
competitors; challenges to patents; changes to applicable laws and
regulations, including global health care reforms; and trends toward
health care cost containment. A further list and description of these
risks, uncertainties and other factors can be found in Johnson &
Johnson's most recent Annual Report on Form 10-K, including in Exhibit
99 thereto, and the company's subsequent filings with the Securities and
Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com
or on request from Johnson & Johnson. None of the Janssen
Pharmaceutical Companies or Johnson & Johnson undertakes to update
any forward-looking statement as a result of new information or future
events or developments.
FONTE Janssen Sciences Ireland UC
0 Comentarios